Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification

Journal of Clinical Pathology

Volumn 66, Issue 10, 2013, Pages 832-838

  Kerr, Keith M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; CRIZOTINIB; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; K RAS PROTEIN; PEMETREXED; PROTEIN P40; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1;

BRONCHUS MUCOSA; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PROGNOSIS; CLINICAL DECISION MAKING; CYTOLOGY; DISEASE CLASSIFICATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG RESECTION; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MEDICAL SOCIETY; MOLECULAR PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SMOKING; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; WORLD HEALTH ORGANIZATION;

DIAGNOSIS; IMMUNOCYTOCHEMISTRY; LUNG CANCER; MOLECULAR PATHOLOGY; ONCOLOGY;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; HUMANS; LUNG; LUNG NEOPLASMS; MUTATION; PATHOLOGY, MOLECULAR;

EID: 84884988668     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201519     Document Type: Review

References (70)

1. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011.;6:244-85.
2. Colby TV, Noguchi M, Henschke C, et al. Adenocarcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organisation classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC press, 2004:35-44.
3. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathol 2009.;54:12-27.
4. Kerr KM, Fraire AE. Pre-invasive diseases. In: Tomashefski J, Cagle P, Farver C Dail & hammar's pulmonary pathology. 3rd edn. New York: Springer, 2008:158-215.
5. Kerr KM, Fraire AE, Pugatch B, et al. Atypical adenomatous hyperplasia. In: Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organisation classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC press, 2004:73-5.
6. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002;26:767-73. (Pubitemid 34546942)
7. Ullman R, Bongiovanni M, Halbwedl I, et al. Bronchiolar columnar cell dysplasia-genetic analysis of a novel preneoplastic lesion of peripheral lung. Virchows Archiv 2003.;442:429-36. (Pubitemid 36718309)
8. Pankiewicz W, Sulewska A, Niklinska W, et al. Immunoexpression of P16INK4a, Rb and TP53 proteins in bronchiolar columnar cell dysplasia (BCCD) in lungs resected due to primary non-small cell lung cancer. Folia Histochem Cytobiol 2008.;46:89-96.
9. Minami Y, Matsuno Y, Iijima T, et al. Prognostication of small-sized primary pulmonary adenocarcinomas by histopathological and karyometric analysis. Lung Cancer 2005;48:339-48. (Pubitemid 40693619)
10. Ikeda K, Awai K, Mori T, et al. Differential diagnosis of ground-glass opacity nodules: CT number analysis by three-dimensional computerized quantification. Chest 2007;132:984-90.
11. Kodama K, Higashiyama M, Yokouchi H, et al. Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning. Lung Cancer 2001;33:17-25. (Pubitemid 32586777)
12. Noguchi M, Morokawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995;75:2844-52.
13. Yokose T, Suzuki K, Nagai K, et al. Favourable and unfavourable morphological prognostic factors in peripheral adenocarcinoma of the lung 3cm or less in diameter. Lung Cancer 2000;29:179-88.
14. Sakurai H, Maeshima A, Watanabe S, et al. Grade of stromal invasion in small adenocarcinoma of the lung. Histopathological minimal invasion and prognosis. Am J Surg Pathol 2004;28:198-206. (Pubitemid 38124728)
15. Kerr KM, Devereux G, Chapman AD, et al. Is survival after surgical resection of lung cancer influenced by the presence of atypical adenomatous hyperplasia (AAH)? J Thorac Oncol 2007;2(Suppl. 4):S401-2.
16. Takigawa N, Segawa Y, Nakata M, et al. Clinical investigation of atypical adenomatous hyperplasia of the lung. Lung Cancer 1999;25:115-21. (Pubitemid 29333090)
17. Logan PM, Miller RR, Evans K, et al. Bronchogenic carcinoma and coexistent bronchioloalveolar cell adenomas. Assessment of radiologic detection and follow-up in 28 patients. Chest 1996;109:713-17. (Pubitemid 26086939)
18. Suzuki K, Nagai K, Yoshida J, et al. The prognosis of resected lung carcinoma associated with atypical adenomatous hyperplasia: a comparison of the prognosis of well-differentiated adenocarcinoma associated with atypical adenomatous hyperplasia and intrapulmonary metastasis. Cancer 1997;79:1521-6. (Pubitemid 27154782)
19. Nawa T, Nakagawa T, Kusano S, et al. Lung cancer screening using low-dose spiral CT. Results of baseline and 1-year follow-up studies. Chest 2002;122:15-20. (Pubitemid 34754137)
20. Xu X, Chung JH, Jheon S, et al. The accuracy of frozen section diagnosis of pulmonary nodules: evaluation of inflation method during intraoperative pathology consultation with cryosection. J Thorac Oncol 2010;5:39-44.
21. Nomori H, Horio H, Naruke T, et al. A case of multiple atypical adenomatous hyperplasia of the lung detected by computed tomography. Jpn J Clin Oncol 2001.;31:514-16. (Pubitemid 33039768)
22. Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and CT imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005.;23:3279-87. (Pubitemid 46211352)
23. Travis WD, Garg K, Franklin WA, et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 WHO Pathologic criteria. J Thorac Oncol 2006;1:s13-19. (Pubitemid 47181353)
24. Lederlin M, Puderbach M, Muley T, et al. Correlation of radio- and histomorphological pattern of pulmonary adenocarcinoma. Eur Respir J 2012. [Epub ahead of print ].
25. Boland JM, Wampfler JA, Yang P, et al. Adenocarcinoam in situ, minimally ivasibe adenocarcinoma and invasive pulmonary adenocarcinoma-evaluation of interobserver agreement in 294 nodules wit hsurvival analysis. Mod Pathol 2012;25 (Suppl. 2):474A.
26. Thunnissen E, Beasley MB, Borczuk AC, et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 2012;25:1574-83.
27. Kerr KM, Fyfe MN, Nicolson MC, et al. Influence of tumour patterns in mixed-type adenocarcinoma on post-operative survival. J Thorac Oncol 2007;2(Suppl. 4): S801-2.
28. Roh MS, Lee JI, Choi PJ, et al. Relationship between micropapillary component and micrometastasis in the regional lymph nodes of patients with stage 1 lung adenocarcinoma. Histopathol 2004;45:580-6. (Pubitemid 40029817)
29. Makimoto Y, Nabeshima K, Iwasaki H, et al. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (≤20mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours). Histopathol 2005.;46:677-84. (Pubitemid 40834827)
30. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011.;24:653-64.
31. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival? J Thorac Oncol 2011;6:1496-504.
32. Warth A, Muley T, Meister M, et al. The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival. J Clin Oncol 2012;30:1438-46.
33. Kadota K, Colovos C, Suzuki K, et al. FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage 1 lung adenocarcinoma. Ann Surg Oncol 2012;19:3598-3605.
34. Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009;33:1752-64.
35. Thunnissen E, Belien JAM, Kerr KM, et al. In compressed lung tissue, microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma. Archives Pathol Lab Med 2013 (in press).
36. Warth A, Cortis J, Fink L, et al. Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Arch 2012;461:185-93.
37. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
38. Sun PL, Seol H, Lee HJ, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012;7:323-30.
39. Jokoji R, Yamasaki T, Minami S, et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 2010;63:1066-70.
40. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011.;29:3574-9.
41. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organisation classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC press, 2004.
42. Thomas JS, Lamb D, Ashcroft T, et al. How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party. Thorax 1993;48:1135-9. (Pubitemid 23336832)
43. Burnett RA, Howatson SR, Lang S, et al. Observer variability in histopathological reporting of non-small cell carcinoma on bronchial biopsy specimens. J Clin Pathol 1996.;49:130-3. (Pubitemid 26064918)
44. Cataluña JJ, Perpiñá M, Greses JV, et al. Cell type accuracy of bronchial biopsy specimens in primary lung cancer. Chest 1996;109:1199-203. (Pubitemid 26145656)
45. Matsuda M, Horai T, Nakamura S, et al. Bronchial brushing and bronchial biopsy: comparison of diagnostic accuracy and cell typing reliability in lung cancer. Thorax 1986.;41:475-8. (Pubitemid 16089183)
46. Chuang MT, Marchevsky A, Teirstein AS, et al. Diagnosis of lung cancer by fibreoptic bronchoscopy : problems in the histological classification of non-small cell carcinomas. Thorax 1984;39:175-8. (Pubitemid 14154222)
47. Edwards SL, Roberts C, McKean ME, et al. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000;53:537-40. (Pubitemid 30432112)
48. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trail comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004;22:2184-91. (Pubitemid 41095154)
49. Scagliotti GV, Parikh P, Pawel JV, et al. Phase III study comparing Cisplatin plus Gemcitabine with Cisplatin plus Pemetrexed in chemotherapy-naïve patients with advanced-stage Non-small cell lung cancer. J Clin Oncol 2008;26:1-10.
50. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010;5:442-7.
51. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15-25.
52. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34:1805-11.
53. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011.;117:3416-23.
54. Wallace WA, Rassl DM. Accuracy of cell typing in nonsmall cell lung cancer by EBUS/EUS-FNA cytological samples. Eur Respir J 2011;38:911-7.
55. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012.;25:405-15.
56. Turner BM, Cagle PT, Sainz IM, et al. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med 2012.;136:163-71.
57. Pao W, Iafrate AJ, Su Z. Genetically informed lung cancer medicine. J Pathol 2011.;223:230-40.
58. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011.;12:175-80.
59. Kerr KM. Adenocarcinoma. In: Cagle P, Allen TC, Beasley MB, et al. Molecular pathology of lung cancer. New York: Springer, 2012:119-62.
60. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150:1107-20.
61. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
62. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
63. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-9.
64. D'Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011;29:2066-70.
65. Lee SY, Kim MJ, Jin G, et al. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010.;5:1734-40.
66. Helland Å, Skaug HM, Kleinberg L, et al. EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J Thorac Oncol 2011;6:947-50.
67. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012;18:1167-76.
68. Felip E, Gridelli C, Baas P, et al. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011.;22:1507-19.
69. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med 2012;136:1-17.
70. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of Lung Adenocarcinoma in Resected Specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med 2012;136:1-23.